‘Is curing patients a sustainable business model?’ That’s what Goldman Sachs analysts asked in an April 2018 report on ‘The Genome Revolution’. The analysts didn’t think so, arguing that there was little money to be made on ‘one shot cures’. But there is endless money to be made from chronically injured people, they argued.
- Unlimited access to spectator.com.au and app
- The weekly edition on the Spectator Australia app
- Spectator podcasts and newsletters
- Full access to spectator.co.uk
Unlock this article
You might disagree with half of it, but you’ll enjoy reading all of it. Try your first month for free, then just $2 a week for the remainder of your first year.